Taft Acts as Legal Counsel to Advanced NanoTherapies in Strategic Investment
Taft is pleased to have acted as legal counsel to Advanced NanoTherapies (ANT) in a $4 million Series A extension from a prominent undisclosed strategic medical device company. The investment will be used for ANT’s clinical programs and to accelerate the path toward U.S. IDE approval for the SirPlux Duo Drug-Coated Balloon.
ANT is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery. Read the release here.
Taft’s legal team included Brandi Weekley and Abe Wehbi.
In This Article
You May Also Like
Meister Appointed Co-Chair of ABA RPTE Committee Hayden Speaks at Vistage Executive Summit 2024